ArticleBritish journal of pharmacology2000
Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.
Article in British journal of pharmacology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 245 citations in OpenAlex.
- Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.British journal of clinical pharmacology · 2009Trial
- No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.British journal of clinical pharmacology · 2002Trial
- Urotensin II evokes potent vasoconstriction in humans in vivo.British journal of pharmacology · 2002Trial
- Current and future strategies for targeting the endothelin pathway in cardiovascular disease.Nature cardiovascular research · 2023Review
- Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.International journal of hypertension · 2020Article
- Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Article
- Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?Journal of endocrinological investigation · 2019Article
- Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits.Frontiers in physiology · 2017Article
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.Rheumatology international · 2016Article
- Plasma urotensin-2 level and Thr21Met but not Ser89Asn polymorphisms of the urotensin-2 gene are associated with migraines.The journal of headache and pain · 2016Article
- The relationship between coronary slow flow phenomenon and urotensin-II: A prospective and controlled study.Anatolian journal of cardiology · 2015Article
- Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.Inflammation · 2014Article
- The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.British journal of pharmacology · 2013Article
- Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.Inflammation · 2013Article
- Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma.Frontiers in pharmacology · 2013Article
- Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.Journal of amino acids · 2013Article
- In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.Frontiers in endocrinology · 2012Article
- A closer look at the role of urotensin II in the metabolic syndrome.Frontiers in endocrinology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have determined the distribution of receptors for human urotensin-II (U-II) in human and rat CNS and peripheral tissues. In rat, [(125)I]-U-II binding density was highest in the abducens nucleus of brainstem (139.6+/-14 amol mm(-2)). Moderate levels were detected in dorsal horn of spinal cord and lower levels in aorta (22. 5+/-6 amol mm(-2)). In human tissues density was highest in skeletal muscle and cerebral cortex ( approximately 30 amol mm(-2)), with lower levels (<15 amol mm(-2)) in kidney cortex and left ventricle. Little binding was identified in atria, conducting system of the heart and lung parenchyma. Receptor density was less in human coronary artery smooth muscle (14.6+/-3 amol mm(-2), n=10) than rat aorta with no significant difference between normal and atherosclerotic vessels. In human skeletal muscle [(125)I]-U-II bound to a single receptor population with K(D)=0.24+/-0.17 nM and B(max)=1.97+/-1.1 fmol mg(-1) protein (n=4). U-II contracted human coronary, mammary and radial arteries, saphenous and umbilical veins with sub-nanomolar EC(50) values. U-II was 50 times more potent in arteries and <10 times more potent in veins than endothelin-1 (ET-1). The maximum response to U-II ( approximately 20% of control KCl) was significantly less than to ET-1 ( approximately 80% KCl). In contrast, in rat aorta, U-II and ET-1 were equipotent with similar maximum responses. This is the first report of high affinity receptors for [(125)I]-U-II in human CNS and peripheral tissues. This peptide produces potent, low efficacy, vasoconstriction in human arteries and veins. These data suggest a potential role for U-II in human physiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.